AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21907422 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg once daily on top of conventional treatment
Number of subjects: 91
Study 21907422 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 91
Study 21719107 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus insulin glulisine (glargine/glulisine)
Number of subjects: 197
Study 21719107 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin analogues
Number of subjects: 197
Study 18160344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (nurse-led lifestyle counselling and preparation for surgery at monthly intervals)
Number of subjects: 188
Study 18160344 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 188
Study 18160344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 188
Study 18160344 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study 16822451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and extended-release dipyridamole
Number of subjects: 0
Study 16822451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 0
Study 16822451 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 16822451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and a thieno-pyridine
Number of subjects: 0
Study 14679093 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (Ins group)
Number of subjects: 54
Study 14679093 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (SU group)
Number of subjects: 54
Study 15478858 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori infection
Number of subjects: 0
Study 10424979 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite material (Belle Glass)
Number of subjects: 40
Study 10424979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic material (SR Isosit)
Number of subjects: 40
Study 10424979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite material (Empress)
Number of subjects: 40
Study 10424979 — intervention group
Group type: COMPARATOR
Intervention: Control group (unprepared teeth)
Number of subjects: 40
Study 8688986 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg x 2/day) with amoxycillin (1500 mg/day)
Number of subjects: 237
Study 8688986 — intervention group
Group type: COMPARATOR
Intervention: Placebo with amoxycillin (1500 mg/day)
Number of subjects: 237
Study 2244610 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V potassium (40 to 50 mg/kg per day for 10 days)
Number of subjects: 73
Study 2244610 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (30 to 40 mg/kg per day for 10 days)
Number of subjects: 73
Study 2244610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin monohydrate (40 to 50 mg/kg per day for 10 days)
Number of subjects: 73
Study 403551 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 70
Study 403551 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (8 mug/kg)
Number of subjects: 70
Study 403551 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (16 and 32 mug/kg)
Number of subjects: 70
Study 403551 — intervention group
Group type: EXPERIMENTAL
Intervention: Methscopolamine (8 and 16 mug/kg)
Number of subjects: 70
Study 403551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31196169 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Triple B for Baby (ETPB) plus care as usual (CAU)
Number of subjects: 6
Study 31196169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mellow Bumps (MB) plus care as usual (CAU)
Number of subjects: 6
Study 31196169 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 6
Study 25682951 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider/clinic-based recruitment
Number of subjects: 1228
Study 25682951 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail
Number of subjects: 1228
Study 25682951 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochures/flyers
Number of subjects: 1228
Study 25682951 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based recruitment
Number of subjects: 1228
Study 25682951 — intervention group
Group type: EXPERIMENTAL
Intervention: Word of mouth
Number of subjects: 1228
Study 23893145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus exercises
Number of subjects: 40
Study 23893145 — intervention group
Group type: COMPARATOR
Intervention: Traditional balance training program (T group)
Number of subjects: 40
Study 21241460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gram of polyunsaturated fatty acids
Number of subjects: 120
Study 21241460 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 grams of polyunsaturated fatty acids
Number of subjects: 120
Study 21241460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19128368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant followed by Metformin
Number of subjects: 20
Study 19128368 — intervention group
Group type: COMPARATOR
Intervention: Metformin only
Number of subjects: 20
Study 17563165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 61
Study 17563165 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy (LT)
Number of subjects: 61
Study 17563165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CBT + LT
Number of subjects: 61
Study 17563165 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact/delayed LT control (MCDT)
Number of subjects: 61
Study 15459300 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 1095
Study 15459300 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 1095
Study 11437206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic chair with movable seat and back rest
Number of subjects: 10
Study 11437206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic chair with freely movable seat and back rest
Number of subjects: 10
Study 11437206 — intervention group
Group type: COMPARATOR
Intervention: Fixed chair with fixed seat and back rest
Number of subjects: 10
Study 9709409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10
Study 9709409 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 10
Study 7976695 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) - 30 mg weekly for one month, then monthly for one year
Number of subjects: 66
Study 7976695 — intervention group
Group type: COMPARATOR
Intervention: Interferon Alpha 2B (IFN) - 50 million units weekly for 3 months, then monthly for one year
Number of subjects: 66
Study 2736920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (KET)
Number of subjects: 26
Study 2736920 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 26
Study 29912570 — intervention group
Group type: EXPERIMENTAL
Intervention: CQR-300 (300 mg daily)
Number of subjects: 67
Study 29912570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch, 300 mg daily)
Number of subjects: 67
Study 28284844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (target dose: 15-20mg/week)
Number of subjects: 7000
Study 28284844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study 25967706 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia-based cream (Bosexil(R))
Number of subjects: 0
Study 25967706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 23574582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 42
Study 23574582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21324563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 1409
Study 21324563 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1409
Study 19690523 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) delivered in person
Number of subjects: 188
Study 19690523 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) delivered primarily by telephone
Number of subjects: 188
Study 19690523 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 188
Study 17685703 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+P gel (0.15 g CHO + 0.038 g protein x kg BW(-1))
Number of subjects: 13
Study 17685703 — intervention group
Group type: COMPARATOR
Intervention: CHO gel (0.15 g CHO x kg BW(-1))
Number of subjects: 13
Study 17685703 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+P gel
Number of subjects: 13
Study 17685703 — intervention group
Group type: COMPARATOR
Intervention: CHO gel
Number of subjects: 13
Study 15228134 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese version of the Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ‐M)
Number of subjects: 63
Study 15228134 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese version of the PFSDQ‐M
Number of subjects: 63
Study 11494442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 30
Study 11494442 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 30
Study 9623431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative skin warming with a water mattress and forced warm air
Number of subjects: 86
Study 9623431 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional management without skin warming)
Number of subjects: 86
Study 7868847 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone for 28 days
Number of subjects: 1507
Study 7868847 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 1507
Study 7868847 — intervention group
Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 1507
Study 7868847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1507
Study 3339726 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin twice weekly for 6 weeks
Number of subjects: 268
Study 3339726 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin for 1 year
Number of subjects: 268
Study 3339726 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after transurethral resection
Number of subjects: 268
Study 30091218 — intervention group
Group type: COMPARATOR
Intervention: SAR425899 (0.01-0.1 mg single ascending doses)
Number of subjects: 108
Study 30091218 — intervention group
Group type: COMPARATOR
Intervention: SAR425899 (daily doses over 21 or 28 days)
Number of subjects: 108
Study 27736032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose unfractionated heparin (100 units kg-1 bolus)
Number of subjects: 49
Study 27736032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (50 units kg-1 bolus)
Number of subjects: 49
Study 24402740 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Resistive Muscle Training (IMT)
Number of subjects: 30
Study 24402740 — intervention group
Group type: COMPARATOR
Intervention: Incentive Spirometry
Number of subjects: 30
Study 23839107 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD tetravalent dengue vaccine (TDV)
Number of subjects: 80
Study 21172891 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m² on day 1 of induction course 1 with various induction schedules
Number of subjects: 1113
Study 21172891 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytarabine
Number of subjects: 1113
Study 21172891 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with GO
Number of subjects: 1113
Study 16884899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (extra support and education through group discussions)
Number of subjects: 60
Study 16884899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 60
Study 16884899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 15734771 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous left ventricular assist device (VAD) support
Number of subjects: 41
Study 15734771 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP) support
Number of subjects: 41
Study 15734771 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD support
Number of subjects: 41
Study 15734771 — intervention group
Group type: COMPARATOR
Intervention: IABP support
Number of subjects: 41
Study 12487322 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata extract SHA-10 fixed combination, Kan Jang, taken for 5 days
Number of subjects: 185
Study 12487322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 9796558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (250 mg b.d. for 5 days)
Number of subjects: 684
Study 9796558 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (250 mg b.d. for 7 days)
Number of subjects: 684
Study 9796558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 684
Study 9796558 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 684
Study 8585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine using immunopotentiating reconstituted influenza virosomes (IRIV)
Number of subjects: 0
Study 8585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine using IRIV with all five vaccines
Number of subjects: 0
Study 8585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine with halved quantity of Di‐Te antigen
Number of subjects: 0
Study 8585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Di‐Te vaccination in the combination
Number of subjects: 0
Study 8585285 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccinations
Number of subjects: 0
Study 8585285 — intervention group
Group type: COMPARATOR
Intervention: Alum‐adsorbed single vaccines
Number of subjects: 0
Study 2495813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg alone
Number of subjects: 18
Study 2495813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg + Atenolol 25 mg
Number of subjects: 18
Study 2495813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg + Nifedipine retard 20 mg
Number of subjects: 18
Study 2495813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 30 mg + Glyceryl trinitrate 500 micrograms
Number of subjects: 18
Study 1118271 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical education program with an emphasis on recreational games
Number of subjects: 25
Study 1118271 — intervention group
Group type: COMPARATOR
Intervention: Perceptual‐motor instruction
Number of subjects: 25
Study 29703990 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia with propofol sedation
Number of subjects: 626
Study 29703990 — intervention group
Group type: COMPARATOR
Intervention: Control group (propofol sedation without topical pharyngeal anesthesia)
Number of subjects: 626
Study 27659698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Number of subjects: 0
Study 25270901 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement in small aortic annulus tertile
Number of subjects: 1932
Study 25270901 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement in large aortic annulus tertile
Number of subjects: 1932
Study 25270901 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve replacement
Number of subjects: 1932
Study 25270901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized continued access cohort in large aortic annulus tertile
Number of subjects: 1932
Study 25270901 — intervention group
Group type: EXPERIMENTAL
Intervention: Large aortic annulus tertile
Number of subjects: 1932
Study 22353786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone cream (0.1%)
Number of subjects: 0
Study 22353786 — intervention group
Group type: COMPARATOR
Intervention: Mometasone comparator (fatty cream with mometasone furoate 0.1%)
Number of subjects: 0
Study 20201689 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 204
Study 20201689 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 204
Study 18400807 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (Pfizer's UK‐427857, Selzentry or Celsentri)
Number of subjects: 0
Study 18400807 — intervention group
Group type: COMPARATOR
Intervention: R5 virus determination test (tropism test)
Number of subjects: 0
Study 18400807 — intervention group
Group type: COMPARATOR
Intervention: Alternative assays
Number of subjects: 0
Study 16385907 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 16385907 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study 12638646 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI antidepressants
Number of subjects: 0
Study 12638646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0
Study 12638646 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 11239615 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA/E(2)C (Lunelle Monthly Contraceptive Injection)
Number of subjects: 0
Study 11239615 — intervention group
Group type: COMPARATOR
Intervention: Other oral contraceptives
Number of subjects: 0
Study 11239615 — intervention group
Group type: COMPARATOR
Intervention: NET/EE (Ortho-Novum 7/7/7)
Number of subjects: 0
Study 8986246 — intervention group
Group type: EXPERIMENTAL
Intervention: E.P.D. (Enzyme Potentiated Desensitization) immunotherapy, administered via intradermal injection at extremely low doses once a year for seasonal allergies and twice a year for non-seasonal allergies
Number of subjects: 35
Study 1592650 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant portal infusion (5‐Fluorouracil, Mitomycin C)
Number of subjects: 533
Study 1592650 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery alone
Number of subjects: 533
Study 6693604 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% anthralin ointment for 10 minutes daily
Number of subjects: 0
Study 6693604 — intervention group
Group type: COMPARATOR
Intervention: Conventional strength (0.1%-0.5%) anthralin ointment overnight
Number of subjects: 0
Study 6693604 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration anthralin (0.5%-3%) for short contact periods of 10 minutes daily
Number of subjects: 0
Study 6693604 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid, difluorosone diacetate
Number of subjects: 0
Study 30810273 — intervention group
Group type: EXPERIMENTAL
Intervention: Signing intervention group (mothers received signing instructions)
Number of subjects: 228
Study 30810273 — intervention group
Group type: COMPARATOR
Intervention: Control group (mothers did not receive signing instructions)
Number of subjects: 228
Study 30810273 — intervention group
Group type: EXPERIMENTAL
Intervention: Signing intervention group
Number of subjects: 228
Study 30810273 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 30810273 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 228
Study 29164181 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (continuous wavelength of 2,940 nm)
Number of subjects: 20
Study 29164181 — intervention group
Group type: COMPARATOR
Intervention: Scalpel technique
Number of subjects: 20
Study 27005817 — intervention group
Group type: EXPERIMENTAL
Intervention: G allele carriers of rs13431554
Number of subjects: 674
Study 24910422 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based skill-building intervention
Number of subjects: 75
Study 24910422 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 75
Study 23018805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 654
Study 19882176 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 150-mg oral dose of casopitant
Number of subjects: 810
Study 19882176 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day IV/oral casopitant
Number of subjects: 810
Study 19882176 — intervention group
Group type: COMPARATOR
Intervention: Control (IV ondansetron/dexamethasone alone)
Number of subjects: 810
Study 19882176 — intervention group
Group type: COMPARATOR
Intervention: Single oral casopitant vs Control
Number of subjects: 810
Study 19882176 — intervention group
Group type: COMPARATOR
Intervention: 3-day IV/oral casopitant vs Control
Number of subjects: 810
Study 16889952 — intervention group
Group type: EXPERIMENTAL
Intervention: Flixotide Diskus (FP) 500-0 mcg/day
Number of subjects: 282
Study 16889952 — intervention group
Group type: COMPARATOR
Intervention: Pulmicort Turbuhaler (BUD) 800-0 mcg/day
Number of subjects: 282
Study 16529064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (rivastigmine)
Number of subjects: 0
Study 16529064 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 0
Study 16529064 — intervention group
Group type: COMPARATOR
Intervention: Selegiline
Number of subjects: 0
Study 16529064 — intervention group
Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 0
Study 12439737 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 42418
Study 12439737 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping variants in hypertension genes
Number of subjects: 42418
Study 10715673 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day primaquine regimen
Number of subjects: 0
Study 10715673 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day primaquine regimen
Number of subjects: 0
Study 10715673 — intervention group
Group type: COMPARATOR
Intervention: No primaquine treatment
Number of subjects: 0
Study 8557961 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg once a day)
Number of subjects: 41